Abstract
Introduction: The endoscopic resection of large and bulky bladder cancers represents a challenge. To reduce the tumor and make it more easy to resect, we used neoadjuvant short and intensive intravesical mitomycin (MMC) therapy. Methods: Patients with large bladder tumors were evaluated for this study. At cystoscopy, the surgeon evaluated the feasibility of complete resection. In patients where this was not possible, biopsies from the tumor, bladder mucosa, and prostatic urethra were taken. These patients then underwent a short and intensive cytoreductive schedule of intravesical MMC. This was then followed by TUR-BT. Results: Fifteen patients were included in our study. The mean age was 74 years (range: 56–82; SD ±6 years). Mean tumor size was 51 mm (range: 35–65; SD ±8 mm). After neoadjuvant treatment, complete resection was then feasible in all patients. The mean tumor volume after the chemo-resection had reduced to 34 mm (range: 10–50; SD ±13 mm). No adverse effects were reported. Conclusion: Intravesical cytoreductive neoadjuvant MMC as an initial treatment of large NMIBC can be considered safe, effective, and feasible.
References
1.
Burger
M
, Catto
JW
, Dalbagni
G
, Grossman
HB
, Herr
H
, Karakiewicz
P
, et al Epidemiology and risk factors of urothelial bladder cancer
. Eur Urol
. 2013
;63
(2
):234
–41
. .2.
Kamat
AM
, Gee
JR
, Dinney
CP
, Grossman
HB
, Swanson
DA
, Millikan
RE
, et al The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma
. J Urol
. 2006
;175
(3 Pt 1
):881
–5
. .3.
Turker
P
, Bostrom
PJ
, Wroclawski
ML
, van Rhijn
B
, Kortekangas
H
, Kuk
C
, et al Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome
. BJU Int
. 2012
;110
(6
):804
. .4.
Sylvester
RJ
, van der Meijden
AP
, Oosterlinck
W
, Witjes
JA
, Bouffioux
C
, Denis
L
, et al Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
. Eur Urol
. 2006
;49
(3
):466
–7
. .5.
Fernandez-Gomez
J
, Madero
R
, Solsona
E
, Unda
M
, Martinez-Piñeiro
L
, Gonzalez
M
, et al Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model
. J Urol
. 2009
;182
:2195
–203
.6.
Willis
DL
, Fernandez
MI
, Dickstein
RJ
, Parikh
S
, Shah
JB
, Pisters
LL
, et al Clinical outcomes of cT1 micropapillary bladder cancer
. J Urol
. 2015
;193
(4
):1129
–34
. .7.
Raj
GV
, Herr
H
, Serio
AM
, Donat
SM
, Bochner
BH
, Vickers
AJ
, et al Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer
. J Urol
. 2007
;177
(4
):1283
–6
. .8.
Maffezzini
M
, Simonato
A
, Zanon
M
, Raber
M
, Carmignani
G
. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer
. J Urol
. 1996 Jan
;155
(1
):91
–3
. .9.
Rigatti
P
, Lev
A
, Colombo
R
. Combined intravesical chemotherapy with mitomycin C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study
. Eur Urol
. 1991
;20
(3
):204
–10
. .10.
Babjuk
M
, Böhle
A
, Burger
M
, Compérat
E
, Kaasinen
E
, Palou
J
, et al In European Guidelines of European Association of Urology
. 2016
.11.
Epstein
JI
, Amin
MB
, Reuter
VR
, Mostofi
FK
. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee
. Am J Surg Pathol
. 1998
;22
(12
):1435
. .12.
Sauter
G
, Algaba
F
, Amin
MB
, Busch
C
, Cheville
J
, Gasser
T
, et al Tumors of the urinary system: non-invasive urothelial neoplasias
. In: WHO classification of classification of tumors of the urinary system and male genital organs
. Lyon
: IARCC Press
; 2004
.13.
WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. 2016, Lyon, France
.14.
Humphrey
PA
, Moch
H
, Cubilla
AL
, Ulbright
TM
, Reuter
VE
. The 2016 WHO classification of tumours of the urinary system and male genital organs – part B: prostate and bladder tumours
. Eur Urol. July
. 2016
;70
(1
):106
–19
.15.
Chou
R
, Gore
JL
, Buckley
D
, Fu
R
, Gustafson
K
, Griffin
JC
, et al Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis
. Ann Intern Med
. 2015
;163
(12
):922
–31
. .16.
Colombo
R
, Da Pozzo
LF
, Lev
A
, Freschi
M
, Gallus
G
, Rigatti
P
. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer
. J Urol
. 1996 Apr
;155
(4
):1227
–32
. .17.
Colombo
R
, Rocchini
L
, Suardi
N
, Benigni
F
, Colciago
G
, Bettiga
A
. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomized phase 2 study
. Eur Urol
. 2012
;62
:797
–802
.18.
Colombo
R
, Da Pozzo
LF
, Lev
A
, Salonia
A
, Rigatti
P
, Leib
Z
, et al Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors
. J Urol
. 1998
;159
(3
):783
–7
. .19.
Gore
JL
, Lai
J
, Setodji
CM
, Litwin
MS
, Saigal
CS
. Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis
. Cancer
. 2009
;115
(5
):988
–96
.© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
